A letter to editor - Critical appraisal on "Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France."

Eur J Obstet Gynecol Reprod Biol X. 2024 Aug 2:23:100332. doi: 10.1016/j.eurox.2024.100332. eCollection 2024 Sep.

Authors

Juan-Enrique Schwarze¹, Vivek Chaudhari², Susana Montenegro¹, Claire Castello-Bridoux³, Cristina Masseria⁴, Claudia Roeder⁴

Affiliations

¹ Merck Healthcare, Merck KGaA, Darmstadt, Germany.
² EMD Serono Inc., Rockland, MA, USA.
³ Merck Santé, France, an affiliate of Merck KGaA, Darmstadt,Germany.
⁴ AESARA Europe, Zug, Switzerland.

No abstract available